Premium
Ethyl‐eicosapentaenoic acid treatment in Huntington's disease: A placebo‐controlled clinical trial
Author(s) -
Ferreira Joaquim J.,
Rosser Anne,
Craufurd David,
Squitieri Ferdinando,
Mallard Nicholas,
Landwehrmeyer Bernhard
Publication year - 2015
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.26308
Subject(s) - placebo , eicosapentaenoic acid , clinical global impression , clinical endpoint , medicine , clinical trial , huntington's disease , rating scale , adverse effect , psychology , physical therapy , disease , chemistry , fatty acid , pathology , biochemistry , developmental psychology , polyunsaturated fatty acid , alternative medicine
Background It has been suggested that treatment with ethyl‐eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine‐adenine‐guanine repeat numbers of <45. Methods This multicenter, randomized, double‐blind, placebo‐controlled 6‐month trial compared the effects of ethyl‐EPA versus placebo on 290 subjects with mild‐to‐moderate HD. The primary endpoint was the change from baseline to 6 months in the Total Motor Score 4 (TMS‐4) component of the Unified Huntington's Disease Rating Scale (UHDRS). Secondary endpoints included change from baseline in UHDRS subscores and Clinical Global Impression (CGI). Results No significant differences in TMS‐4 scores were noted between treatment groups. Similarly, there were no significant differences between groups on any of the UHDRS subscores or CGI scores. Conclusion Ethyl‐EPA was not beneficial in patients with HD during 6 months of placebo‐controlled evaluation. © 2015 International Parkinson and Movement Disorder Society